# PSMAddition (NCT04720157)

> An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04720157
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Novartis Pharmaceuticals
- Conditions: Prostatic Neoplasms
- Interventions: 177Lu-PSMA-617; 68Ga-PSMA-11; ARDT; ADT
- Enrollment: 1140
- Primary outcome: Radiographic Progression Free Survival (rPFS)

## Commentary we found

- X threads: 139
- YouTube: 85
- Podcasts: 68
- X videos: 7

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=psmaddition-nct04720157

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04720157", "email": "<work email>"}; the inbox owner confirms by the emailed link.